Results 131 to 140 of about 414,323 (331)
Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment
BMEMat, EarlyView.Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan +8 more
wiley +1 more source
Biomarker ResearchInhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang +9 more
doaj +1 more source
An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population
Clinical Anatomy, EarlyView.ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley +1 more source
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma [PDF]
, 2016 XS Xu +13 more
openalex +1 more source
Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
American Journal of Hematology, EarlyView.
Rong Wang +9 more
wiley +1 more source
Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Clinical trials are essential to understand the benefit‐harm profile of new drugs. Lack of adequate representation in age and sex ratio in clinical trials can result, for example, in higher side effects for underrepresented patients. We quantified differences in age and sex ratios between trial and target populations of new drugs approved by the FDA ...
Miquel Serra‐Burriel +2 more
wiley +1 more source
Mechanisms of action and clinical development of elotuzumab [PDF]
, 2017 Colonna, Marco, Ritchie, David
core +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz +15 more
wiley +1 more source